Bionano Genomics Inc expected to post a loss of 21 cents a share - Earnings Preview

* Bionano Genomics Inc is expected to show a fall in quarterly revenue when it reports results on November 6 (estimated) for the period ending September 30 2024

* The San Diego California-based company is expected to report a 15.7% decrease in revenue to $7.854 million from $9.32 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on October 10 2024, for the period ended September 30, was for revenue between $6.50 million and $6.80 million.

* ​LSEG's mean analyst estimate for Bionano Genomics Inc is for a loss of 21 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Bionano Genomics Inc is 1.90​, above​ its last closing price of $0.28. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.41 -0.42 -0.22 Beat 47.2

Mar. 31 2024 -0.64 -0.64 -0.51 Beat 20.9

Dec. 31 2023 -0.87 -0.87 -0.41 Beat 53​

Sep. 30 2023 -0.92 -0.97 -1.00 Missed -3.1

​​Jun. -1.00 -1.03 -1.24 Missed -20

30 2023

Mar. 31 2023 -1.10 -1.10 -1.20 Missed -9.1​

Dec. 31 2022 -1.14 -1.10 -1.30 Missed -18.2

Sep. 30 2022 -1.18 -1.15 -1.10 Beat 4.3

This summary was machine generated November 4 at 23:12 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)